Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00883090 · ClinicalTrials.gov registry record · Phase 2
A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
A Phase 2 study of Factor XIII Deficiency, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 6
- Study locations
NCT00883090 is a Phase 2 study of Factor XIII Deficiency that has completed, run by CSL Behring. The registered enrollment target is 15 participants. The trial reports 6 study locations across 4 states.
The verdict
NCT00883090, a Phase 2 study of Factor XIII Deficiency, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 6
- Study locations
Study Summary
Congenital deficiency of Factor XIII is an extremely rare hereditary disorder associated with potentially life-threatening bleeding. This study will evaluate the safety and recommended (best) amount or level of Factor XIII in a patient's blood. Factor XIII Concentrate (Human) is given to people whose blood is lacking Factor XIII. Factor XIII Concentrate (Human) works by assisting your blood in the usual clotting process, thereby preventing bleeding.
Conditions Studied
Interventions
- BIOLOGICAL FXIII Concentrate (Human)
Study Locations (6)
California
- Study Site - Orange
- Study Site - San Francisco
- Study Site - Stockton
Alabama
- Study Site - Dothan
Massachusetts
- Study Site - Boston
Other
- Study Site - Santa Cruz de Tenerife
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00883090
The ClinicalTrials.gov registry entry for NCT00883090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Factor XIII Deficiency appearing as the primary indexed condition, and to 1 intervention - of which FXIII Concentrate (Human) is the first listed.
NCT00883090 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00883090 about?
NCT00883090 is a clinical study titled "A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency". Congenital deficiency of Factor XIII is an extremely rare hereditary disorder associated with potentially life-threatening bleeding. This study will evaluate the safety and recommended (best) amount or level of Factor XIII in a patient's blood. Factor XIII Concentrate (Human) is given to people whos...
What is the current status of trial NCT00883090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2009-05. Estimated completion is 2010-04.
What conditions does trial NCT00883090 study?
This clinical trial studies the following conditions: Factor XIII Deficiency.
What interventions are being tested in trial NCT00883090?
The interventions under investigation include: FXIII Concentrate (Human) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00883090?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00883090 being conducted?
This trial has 6 study locations across Alabama, California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Factor XIII Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.